

527,821

**(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property  
Organization  
International Bureau**



**(43) International Publication Date**  
**22 April 2004 (22.04.2004)**

## PCT

**(10) International Publication Number**  
**WO 2004/033428 A1**

- (51) **International Patent Classification<sup>7</sup>:** C07D 211/58, 413/14, 409/14, 401/14, 471/04, 405/14, 417/14

(21) **International Application Number:** PCT/EP2003/050697

(22) **International Filing Date:** 7 October 2003 (07.10.2003)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**  
PCT/EP02/11328 8 October 2002 (08.10.2002) EP  
PCT/EP02/14836 23 December 2002 (23.12.2002) EP

(71) **Applicant (for all designated States except US):** JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). SOMMEN, François, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DE BOECK, Benoît, Christian, Albert, Ghislain [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN ROOSBROECK, Yves, Emiel, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) **Common Representative:** JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, TJ, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**


  - as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

[Continued on next page]

**(54) Title:** SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS



**(57) Abstract:** The invention concerns substituted 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK<sub>1</sub> antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of emesis, anxiety, depression, pain, pancreatitis and IBS. The compounds according to the invention can be represented by general Formula (I), and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK<sub>1</sub> receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of neurokinin-mediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.

WD 2004/033428 A1



— of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT 03/50697

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 C07D413/14 C07D409/14 C07D401/14 C07D471/04  
C07D405/14 C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/16440 A (JANSSEN PHARMACEUTICA NV ; JANSSENS FRANS EDUARD (BE); SOMMEN FRANCOIS) 9 May 1997 (1997-05-09) cited in the application claims -----	1,6,8

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

28 January 2004

Date of mailing of the international search report

10/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT 03/50697

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9716440	A	09-05-1997	AT 188691 T 15-01-2000
		AU 704155 B2 15-04-1999	
		AU 7493296 A 22-05-1997	
		BR 9611184 A 30-03-1999	
		CA 2234096 A1 09-05-1997	
		CN 1438220 A 27-08-2003	
		CN 1205699 A , B 20-01-1999	
		CY 2177 A 23-08-2002	
		CZ 9801322 A3 16-09-1998	
		DE 69606196 D1 17-02-2000	
		DE 69606196 T2 21-09-2000	
		EA 980404 A1 29-10-1998	
		WO 9716440 A1 09-05-1997	
		EP 0862566 A1 09-09-1998	
		ES 2143238 T3 01-05-2000	
		GR 3033154 T3 31-08-2000	
		HR 960507 A1 28-02-1998	
		HU 9802985 A2 28-10-1999	
		IL 123962 A 11-01-2001	
		JP 11514634 T 14-12-1999	
		JP 3073238 B2 07-08-2000	
		NO 981534 A 24-06-1998	
		NZ 321575 A 28-05-1999	
		PL 327406 A1 07-12-1998	
		PT 862566 T 30-06-2000	
		SI 862566 T1 30-04-2000	
		TR 9800756 T2 21-07-1998	
		TW 460473 B 21-10-2001	
		US 6197772 B1 06-03-2001	
		US 6521621 B1 18-02-2003	
		US RE37886 E1 15-10-2002	
		ZA 9609090 A 29-04-1998	